Get started
Author

Karin Tunblad

Blood‐brain barrier transport and brain distribution of morphine‐6‐glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling
2001 · M René Bouw, Rujia Xie, et al. · British Journal of Pharmacology · 103
PDF
Blood–brain barrier transport of morphine in patients with severe brain trauma
2004 · Per Ederoth, Karin Tunblad, et al. · British Journal of Clinical Pharmacology · 92
PDF
Morphine Blood-Brain Barrier Transport Is Influenced by Probenecid Co-Administration
2003 · Karin Tunblad, E. Niclas Jonsson, et al. · Pharmaceutical Research · 90
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis
2018 · Erik Lindström, Biljana Rizoska, et al. · Journal of Translational Medicine · 72
PDF
An Integrated Model for the Analysis of Pharmacokinetic Data from Microdialysis Experiments
2004 · Karin Tunblad, Margareta Hammarlund-Udenaes, et al. · Pharmaceutical Research · 60
Altered brain exposure of morphine in experimental meningitis studied with microdialysis
2004 · K. Tunblad, P. Ederoth, et al. · Acta Anaesthesiologica Scandinavica · 42
Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain
2016 · Ellen Hewitt, Thomas Pitcher, et al. · Journal of Pharmacology and Experimental Therapeutics · 40
Influence of probenecid on the delivery of morphine-6-glucuronide to the brain
2004 · Karin Tunblad, Margareta Hammarlund-Udenaes, et al. · European Journal of Pharmaceutical Sciences · 39
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data
2008 · Karin Tunblad, Lars Lindbom, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 31
Combining an amyloid‐beta (Aβ) cleaving enzyme inhibitor with a γ‐secretase modulator results in an additive reduction of Aβ production
2014 · Kia Strömberg, Susanna Eketjäll, et al. · FEBS Journal · 23
Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain
2018 · Lilian N. Nwosu, Peter R.W. Gowler, et al. · PAIN Reports · 19
Six months’ treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: results from a randomized double-blind placebo-controlled phase IIA trial
2018 · P.G. Conaghan, M.A. Bowes, et al. · Osteoarthritis and Cartilage · 17
PDF
Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839
2014 · Erik Sparve, Angelica L. Quartino, et al. · Journal of Pharmacology and Experimental Therapeutics · 14
Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig
2013 · Juliette Janson, Susanna Eketjäll, et al. · Pharmaceutical Research · 11
Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials
2026 · Monica T. Hannani, Peder Frederiksen, et al. · Arthritis Research & Therapy · 4
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
2024 · Ruth Plummer, Alastair Greystoke, et al. · Journal of Hepatocellular Carcinoma · 4
PDF
Blood-Brain Barrier Transport of Drugs Across Species with the Emphasis on Health, Disease and Modelling
2004 · Karin Tunblad · Uppsala University Publications (Uppsala University) · 3
Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.
2021 · T.R. Jeffry Evans, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 2
The Cathepsin K inhibitor L-006235 has analgesic and disease modifying properties in the MIA model of osteoarthritis
2016 · J.J. Burston, L. Xu, et al. · Osteoarthritis and Cartilage · 2
Assessment of Differential Treatment Effect Between Predicted Endotype Subgroups of Knee Osteoarthritis in the Miv-711, Ubx0101, and Oral Salmon Calcitonin Trials
2025 · Monica T. Hannani, Peder Frederiksen, et al. · Osteoarthritis and Cartilage · 1
986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
2024 · H. Chon, J. Heo, et al. · Annals of Oncology · 1
PDF
First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).
2024 · Maria Reig, T.R. Jeffry Evans, et al. · Journal of Clinical Oncology · 1
PDF
Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers
2017 · R. Bethell, K. Tunblad, et al. · Journal of Hepatology · 1
Population PKPD Modeling of BACE1 Inhibitor- Induced Reduction in Aβ Levels in vivo.
2012 · Juliette Janson, Susanna Eketjäll, et al. · 1
Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al.
Works count: 42
Citation count: 673
H-index: 13
I10-index: 14
Year
Topic
Type